Association between haemostatic parameters at diagnosis and pregnancy outcome in women with pre-eclampsiain south-east Nigeria
DOI:
https://doi.org/10.60787/tnhj.v22i3.598Keywords:
Preeclampsi, maternal outcome, fetal outcome, thrombocytopenia, prothrombin time, activated partial thromboplastin time, coagulation screening testsAbstract
Background Pre-eclampsia complicates 3-5% of pregnancies and is a global cause of perinatal and maternal death. In pre-eclampsia, activated maternal inflammatory response and immune dysfunction culminate in serious derangement in the coagulation and fibrinolytic systems. we aimed to determine if changes in the coagulation system predict severity and outcome of preeclampsia.
Methodology: This was a prospective self-controlled study of pre-eclamptic pregnant women recruited at 28 weeks and followed till delivery. At the point of diagnosis, blood sample for platelet count, prothrombin time and activated partial thromboplastin time was collected. Data was analyzed using IBM SPSS version 20. P value was set at <0.05.
Results: Thirty women with preeclampsia were followed up to delivery in this study. Their mean gestational ages were 33.87± 3.93 and 37.50±2.77 weeks at recruitment and delivery respectively. Of the complications seen in these women, maternal death 16(36.7%) was the most frequent maternal complication while prematurity 23 (76.7%) was the most frequent fetal complication. Ten (33.3%) subjects had thrombocytopenia, 7(23.3%) had isolated prolonged PT, 17(56.7%) had isolated prolonged APTT while 18(60.0%) had both prolonged PT and APTT. Maternal and fetal complications had no significant association with the PT and APTT of the study subjects.
Conclusion: The prevalence rates of thrombocytopenia and derangement in PT and APTT are 10%, 56.7% and 60% respectively in preeclampsia. The prevalence of fetomaternal complications is high in preeclampsia. However, the coagulation derangement showed no associations with these complications and may not serve as predictors of poor pregnancy outcome.
Downloads
References
Helmo FR, Lopes AM, Carneiro AC, Campos CG, Silva PB, Dos Reis MA, et al. Angiogenic and Antiangiogenic Factors in Pre-eclampsia. Pathol Res Pract 2018; 214: 7-14.
Yadav BS, Jain SK, Toppo NA, Dehariya C. A Case Control Study on Serum Uric Acid and Serum Creatinine Levels in Pre-eclampsia Patients of a Tertiary Care Hospital in Jabalpum District of Central India. Int J Res Med Sci 2018; 6: 1519-24.
Ajah LO, Ozonu NC, Ezeonu PO, Lawani LO, Obuna JA, Onwe EO. The Feto-Maternal Outcome of Pre-eclampsia with Severe Features and Eclampsia in Abakaliki, South-East Nigeria. J Clin Diagn Res 2016; 10:18-21.
Ugwuja EI, Ejikeme BN, Ugwu NC, Obeka NC, Akubugwo EI, Obidoa O. Comparison of Plasma Copper, Iron, and Zinc Levels in Hypertensive and Non-hypertensive PregnantWomen in Abakaliki, South-eastern Nigeria. Pak J Nutr 2010; 9: 1136-1140.
American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122:1122-31.
Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: implications for health system strengthening. J Pregnancy. 2011; 2011:481095.i
Peres GM, Mariana M, Cairrão E. Pre-eclampsia and Eclampsia: An Update of the Pharmacological Treatment Applied in Portugal. J Cardiovasc Dev Dis 2018; 5:3. Doi: 10.3390/jcdd5010003.
Balogun AO, Khanagura RK, Krejel HR, Amro FH, Sibai BM, Chauhan SP. Preterm Pre-eclampsia with Severe Features: Composite Maternal and Neonatal Morbidities Associated with Fetal Growth Restriction. Amer J Perinatol 2018. DOI: 10.1055/S—0037—1617456.
Priyadarshini GP, Mohanty RR. Assessment of coagulation profile and its correlation with severity of preeclampsia in women of odisha-a comparative cross-sectional study. Inter J Basic Applied Physiol. 2014; 3:234-40.
Youssef L, Miranda J, Blasco M, Paules C, Crovetto F, Palomo M, et al. Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. Scientific reports. 2021;11:1-3.
Han L, Liu X, Li H, Zou J, Yang Z, Han J, et al. Blood coagulation parameters and platelet indices: changes in normal and pre-eclamptic pregnanciesand predictive values for pre-eclampsia. Plos one 2014; 9:1-14
Townsley DM. Haematologic complications of pregnancy. Seminars in Haemat 2013; 50:1-1413.Irminger-Finger I, Jastrow N, Irion O. Preeclampsia: a danger growing in disguise. Int J Biochem cell Biol 2008; 40: 1979-1983.
Al-Husban N, Al-Kuran A, Khadra M, Fram K. Thrombocytopenia in pregnancy: prevalence, causes and fetomaternaloutcome. Clin. Exp. Obstet. Gynecol. -ISSN: 0390-6663 XLVII, n. 1, 2020 doi: 10.31083/j.ceog.2020.01.4945
Nisha S, Amita D, Uma S, Tripathi AK, Pushplata S. Prevalence and characterization of thrombocytopenia in pregnancy in Indian women. Indian J Haematol Blood Transfus. 2012; 28: 77 -81
MayamaM,Morikawa M, Yamada T, Umazume T, Noshiro K, Nakagawa K, Saito Y, et al. Mild thrombocytopenia indicating maternal organ damage in preeclampsia: a cross-sectional study. BMC Pregnancy and Childbirth. 2021; 21:91. Doi:10.1186/s12884-021-03564-4.
Han L., Liu X., Li H., Zou J., Yang Z., Han J., Huang W., Yu L., Zheng Y., Li1 L. Blood coagulation parameters and platelet indices: changes in normal and preeclamptic pregnancies and predictive values for preeclampsia.PLoS One.2014;9: e114488
Thalor N, Singh K, Pujani M, Chauhan V, Argawal C, Ahuja R. A correlation between platelet indices and preeclampsia. Hematol Transfus Cell Ther. 2019; 41: 129-33
Heilmann L, Rath W, Pollow K.Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost. 2007; 13:285–291
Williams VK, Griffiths AB, Carbone S, Hague WM.Fibrinogen concentration and factor VIII activity in women with preeclampsia.Hypertens Pregnancy. 2007;26:415–421.
Tanjung MT, Siddik HD, Hariman H, Koh SC. Coagulation and fibrinolysis in preeclampsia and neonates.Clin Appl Thromb Hemost2005;11:467–473.
Awolola OO, Enaruna NO. Determination of coagulopathy complicating severe preeclampsia and eclampsia with platelet count in a University Hospital, South-South, Nigeria. Trop J Obstet Gynaecol 2016; 33:179-84.
Aadibha PM, Cherian AG, Paul E, Hellan J. Maternal and fetal outcome in preeclampsia in a secondary care hospital in South India. J Family Med Prim Care. 2015; 4: 257-60
Ndiaye K, Portillo E, Ouedraogo D, Mobley A, Babalola S. High-risk advanced maternal age and high parity pregnancy: tacking a neglected need through formative research and action. Glob Health Sci and Pract. 2018; 6: 372 -83.
AlterG, Dribe, M, VanPoppel, F. Widowhood, family size, and post-reproductive mortality: A comparative analysis of three populations in nineteenth-century Europe.Demography 2007;44: 785–806
Hnat MD, Sibai B, Caritis S, et al. for the National Institute of Child Health and Human Development Network of Maternal–Fetal Medicine Units: Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol. 2002; 186:422-426.
Sibai BM. Preeclampsia asa cause of preterm and late preterm (near-term) births. Semin Perinatol. 2006; 30: 16-19
Levine RJ, Ewell MG, Hauth JC, et al: Should the definition of preeclampsia include a rise in diastolic blood pressure of 15 mmHg to a level 90 mmHg in association with proteinuria? Am J Obstet Gynecol. 2000; 183:787-792
Gofton EN, Capwell V, Natale R, et al: Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol. 2001; 185:798-803
Hauth JC, Ewell MG, Levine RJ, et al: Pregnancy outcome in healthy nulliparous women who subsequently developed hypertension. Obstet Gynecol 2000; 95:24-28.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 The Nigerian Health Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
